TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress, as well as the safety and efficacy data from the SunRISe-1 trial.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

Now Viewing

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

Video content above is prompted by the following:

• SunRISe-1 is a phase 2b study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress. Discuss patient demographics and SunRISe-1 clinical trial design.
• Discuss the safety and efficacy data from the SunRISe-1 trial.
  

Related Videos